Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Purpose
This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Tivozanib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals tumor cells to multiply. This helps stop the spread of tumor cells. Giving pembrolizumab and tivozanib together may work better than pembrolizumab alone in treating patients with RCC.
Conditions
- Clear Cell Renal Cell Carcinoma
- Renal Cell Carcinoma (RCC)
- Stage II Renal Pelvis Cancer AJCC v8
- Stage III Renal Pelvis Cancer AJCC v8
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Criteria
Inclusion Criteria:
- • Histologically confirmed diagnosis of RCC with clear cell component with or
without sarcomatoid features following complete resection of the primary tumor
(radical or partial nephrectomy)
- Note: Patients with microscopically positive soft tissue or vascular margins
without gross residual disease are permitted
- Intermediate-high risk RCC:
- pT2 grade 4 or sarcomatoid features, N0M0
- pT3 any grade N0, M0
- High-risk RCC
- pT4, any grade, N0, M0
- pT, any stage., any grade, N+, M0
- cM1 no evidence of disease (NED) RCC
- Participants who have had resection of primary tumor (radical or
partical nephrectomy) and resection or definitive radiation or
ablation of solid, isolated, soft tissue metastases (excluding brain
and bone lesions) at the time of primary tumor removal (synchronous)
or ≤1 year from primary tumor removal (metachronous)
- Surgery (radical or partial nephrectomy or metastasectomy or
ablation) > 4 weeks but =< 16 weeks prior to study registration
with no ongoing complications from surgery
- No evidence of disease at time of randomization as assessed by
investigator by either CT or MRI scan of the brain and chest,
abdomen and pelvis
- No prior systemic treatment for RCC
- Age >= 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status =<
2 (or Karnofsky >= 60%)
- Absolute neutrophil count (ANC) >= 1,000/mm^3
- Platelet count >= 100,000/mm^3
- Hemoglobin >= 8 g/dL
- Total bilirubin =< 3 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic
transaminase [SGOT])/alanine aminotransferase (ALT) (serum
glutamate pyruvate transaminase [SGPT]) =< 3 x upper limit of
normal (ULN)
- Calculated (calc.) creatinine clearance >= 30 mL/min (using
Cockcroft Gault equation or the estimated glomerular filtration
rate from the modification of diet in renal disease trial)
- Urine protein =< 1+ on urine analysis (UA) or urine protein
creatinine ration (UPCR) < 2mg/mg
- Not pregnant and not nursing, because this study involves an
agent that has known genotoxic, mutagenic and teratogenic
effects. Therefore, for women of childbearing potential only, a
negative pregnancy test is required =< 14 days prior to
registration
- HIV status: HIV-infected patients on effective anti-retroviral
therapy with undetectable viral load within 6 months are
eligible for this trial
- Hepatitis
- Hepatitis B: For patients with evidence of chronic hepatitis B virus (HBV)
infection, the HBV viral load must be undetectable on suppressive therapy, if
indicated. Patients with resolved HBV infection, defined as positive hepatitis
B core antibody (anti-HBc) and negative hepatitis B surface antigen (HbsAg),
are eligible
- Hepatitis C: Patients with a history of hepatitis C virus (HCV) infection must
have been treated and cured. For patients with HCV infection who are currently
on treatment, they are eligible if they have an undetectable HCV viral load
- Cardiac Disease: Patients with known history or current symptoms of
cardiac disease, or history of treatment with cardiotoxic agents, should
have a clinical risk assessment of cardiac function using the New York
Heart Association Functional Classification. To be eligible for this
trial, patients should be class IIB or better
- No history of myocarditis
- No history of clinically significant pneumonitis
- No uncontrolled hypertension (systolic blood pressure [BP] > 150 mm Hg or
diastolic BP > 90 mm Hg) documented on 2 consecutive measurements taken at
least 2 hours apart
- No serious non-healing wound, ulcer or bone fracture within 28 days prior
to registration
- No serious/active infection requiring parenteral antibiotics
- No moderate or severe hepatic impairment (child-Pugh B or C)
- No significant bleeding disorders within 1 month prior to registration,
for example:
- Hematemesis, hematochezia or other gastrointestinal bleeding grade 3 or higher
- Hemoptysis of pulmonary bleeding grade 3 or higher
- Hematuria or other genitourinary bleeding grade 3 or higher
- No history of allogeneic organ transplantation
- No history of allergy of hypersensitivity to study drugs or components
- No condition requiring systemic treatment with either corticosteroid (> 10
mg daily or prednisone equivalent) within 14 days of treatment initiation
or other immunosuppressive medications within 30 days of randomization.
Inhaled or topical steroids and adrenal replacement doses ≤10 mg daily
prednisone equivalent are permitted in absence of active autoimmune
disease
- No active peptic ulcer disease, inflammatory bowel disease, ulcerative
colitis or other gastrointestinal condition associated with increased risk
of perforation; history of abdominal fistula, gastrointestinal perforation
or intra-abdominal abscess within 4 weeks prior to registration
- Patients with a prior or concurrent malignancy whose natural history or
treatment does not have the potential to interfere with the safety or
efficacy assessment of the investigational regimen are eligible for this
trial
- No patients with a history of autoimmune disease that has required
systemic treatment in the past 2 years (i.e., with use of disease
modifying agents, corticosteroids > 10 mg/day, or immunosuppressive drugs)
with the following exceptions:
- Replacement therapy (e.g., thyroxine, insulin, physiologic corticosteroid
replacement therapy for adrenal or pituitary insufficiency) is not considered a
form of systemic treatment and is allowed
- Brief (<7 days) use of systemic corticosteroids is allowed when use is
considered standard of care
- Patients with vitiligo, psoriasis, type 1 diabetes mellitus, hypothyroidism, or
resolved childhood asthma/atopy will not be excluded
- Patients requiring intermittent use of bronchodilators, inhaled steroids, or
local steroid injections will not be excluded
- Patients with hypothyroidism that is stable with hormone replacement or
Sjögren's syndrome will not be excluded • Chronic concomitant treatment with
strong CYP3A4 inducers is not allowed. Patients must discontinue the drug 14
days prior to the start of study treatment
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Active Comparator Arm 1 (Pembrolizumab) |
Patients receive pembrolizumab IV on days 1 and 43 of each cycle, or on days 1, 22, 43 and 64 of each cycle. Cycles repeat every 12 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and MRI or CT throughout the trial and may undergo tissue biopsy on study. |
|
|
Experimental Arm 2 (pembrolizumab + tivozanib) |
Patients receive pembrolizumab IV on days 1 and 43 of each cycle and tivozanib PO QD on days 1-21, days 29-49, and days 57-77 of each cycle for up to 6 months. Cycles repeat every 12 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and MRI or CT throughout the trial and may undergo tissue biopsy on study. |
|
Recruiting Locations
Phoenix, Arizona 85004
Tucson, Arizona 85719
Tucson, Arizona 85719
Jonesboro, Arkansas 72401
Little Rock, Arkansas 72205
Site Public Contact
501-686-8274
Auburn, California 95602
Beverly Hills, California 90211
Duarte, California 91010
Irvine, California 92612
Irvine, California 92618
Site Public Contact
877-467-3411
La Jolla, California 92093
Lancaster, California 93534
Los Angeles, California 90033
Los Angeles, California 90033
Site Public Contact
323-865-0451
Los Angeles, California 90048
Site Public Contact
310-423-8965
Modesto, California 95355
Newport Beach, California 92663
Site Public Contact
323-865-0451
Orange, California 92868
Palo Alto, California 94301
Roseville, California 95661
Sacramento, California 95816
Sacramento, California 95817
Site Public Contact
916-734-3089
San Diego, California 92103
San Francisco, California 94115
San Mateo, California 94401
Santa Cruz, California 95065
Sunnyvale, California 94086
Torrance, California 90503
Site Public Contact
877-467-3411
Torrance, California 90505
Upland, California 91786
Vallejo, California 94589
Aurora, Colorado 80045
Site Public Contact
720-848-0650
Colorado Springs, Colorado 80909
Site Public Contact
719-365-2406
Colorado Springs, Colorado 80920
Site Public Contact
719-364-6700
Denver, Colorado 80206
Fort Collins, Colorado 80524
Site Public Contact
970-297-6150
Fort Collins, Colorado 80528
Greeley, Colorado 80631
Highlands Ranch, Colorado 80129
Site Public Contact
720-848-0650
Lone Tree, Colorado 80124
Loveland, Colorado 80538
Site Public Contact
970-203-7083
Avon, Connecticut 06001
Site Public Contact
860-972-4700
Bridgeport, Connecticut 06606
Site Public Contact
860-972-4700
Derby, Connecticut 06418
Fairfield, Connecticut 06824
Fairfield, Connecticut 06824
Greenwich, Connecticut 06830
Guilford, Connecticut 06437
Hartford, Connecticut 06102
Site Public Contact
860-545-5363
Manchester, Connecticut 06042
Site Public Contact
860-972-4700
Meriden, Connecticut 06451
Site Public Contact
866-662-5678
New Britain, Connecticut 06050
Site Public Contact
860-224-5660
New Haven, Connecticut 06520
Stamford, Connecticut 06902
Stamford, Connecticut 06904
Site Public Contact
203-323-8944
Torrington, Connecticut 06790
Trumbull, Connecticut 06611
Waterbury, Connecticut 06708
Waterford, Connecticut 06385
Millville, Delaware 19967
Newark, Delaware 19713
Newark, Delaware 19713
Rehoboth Beach, Delaware 19971
Washington D.C., District of Columbia 20010
Site Public Contact
202-877-8839
Washington D.C., District of Columbia 20037
Site Public Contact
202-741-2210
Gainesville, Florida 32610
Miami, Florida 33176
Site Public Contact
786-596-2000
Atlanta, Georgia 30303
Site Public Contact
404-778-1868
Atlanta, Georgia 30308
Site Public Contact
888-946-7447
Atlanta, Georgia 30322
Site Public Contact
404-778-1868
Atlanta, Georgia 30342
Site Public Contact
404-851-7115
Johns Creek, Georgia 30097
Boise, Idaho 83712
Coeur d'Alene, Idaho 83814
Fruitland, Idaho 83619
Meridian, Idaho 83642
Nampa, Idaho 83687
Post Falls, Idaho 83854
Sandpoint, Idaho 83864
Aurora, Illinois 60506
Barrington, Illinois 60010
Site Public Contact
847-842-4847
Bloomington, Illinois 61704
Canton, Illinois 61520
Carterville, Illinois 62918
Carthage, Illinois 62321
Chicago, Illinois 60611
Chicago, Illinois 60612
Chicago, Illinois 60612
Site Public Contact
312-355-3046
Chicago, Illinois 60657
Site Public Contact
773-296-5360
Crystal Lake, Illinois 60014
Decatur, Illinois 62526
Decatur, Illinois 62526
DeKalb, Illinois 60115
Dixon, Illinois 61021
Site Public Contact
815-285-7800
Downers Grove, Illinois 60515
Effingham, Illinois 62401
Elgin, Illinois 60123
Site Public Contact
847-429-2907
Elmhurst, Illinois 60126
Eureka, Illinois 61530
Galesburg, Illinois 61401
Geneva, Illinois 60134
Glenview, Illinois 60026
Site Public Contact
312-695-1102
Grayslake, Illinois 60030
Site Public Contact
312-695-1102
Hazel Crest, Illinois 60429
Site Public Contact
708-799-9995
Kewanee, Illinois 61443
Lake Forest, Illinois 60045
Libertyville, Illinois 60048
Libertyville, Illinois 60048
Macomb, Illinois 61455
Naperville, Illinois 60540
Site Public Contact
630-646-6075
O'Fallon, Illinois 62269
Oak Brook, Illinois 60523
Oak Lawn, Illinois 60453-2699
Site Public Contact
800-323-8622
Oak Lawn, Illinois 60453
Orland Park, Illinois 60462
Ottawa, Illinois 61350
Palos Heights, Illinois 60463
Park Ridge, Illinois 60068
Site Public Contact
847-384-3621
Pekin, Illinois 61554
Peoria, Illinois 61615
Peru, Illinois 61354
Plainfield, Illinois 60585
Princeton, Illinois 61356
Shiloh, Illinois 62269
Springfield, Illinois 62702
Site Public Contact
217-545-7929
Springfield, Illinois 62702
Site Public Contact
800-444-7541
Springfield, Illinois 62781
Urbana, Illinois 61801
Warrenville, Illinois 60555
Washington, Illinois 61571
Avon, Indiana 46123
Carmel, Indiana 46032
Indianapolis, Indiana 46202
Indianapolis, Indiana 46202
Ames, Iowa 50010
Site Public Contact
515-956-4132
Ames, Iowa 50010
Bettendorf, Iowa 52722
Boone, Iowa 50036
Site Public Contact
515-956-4132
Cedar Rapids, Iowa 52403
Site Public Contact
319-365-4673
Cedar Rapids, Iowa 52403
Site Public Contact
319-363-2690
Fort Dodge, Iowa 50501
Site Public Contact
515-956-4132
Iowa City, Iowa 52242
Site Public Contact
800-237-1225
Jefferson, Iowa 50129
Site Public Contact
515-956-4132
Marshalltown, Iowa 50158
Site Public Contact
515-956-4132
Louisville, Kentucky 40202
Site Public Contact
502-562-3429
Louisville, Kentucky 40207
Louisville, Kentucky 40245
New Orleans, Louisiana 70121
Brewer, Maine 04412
Site Public Contact
800-987-3005
Cumberland, Maryland 21502
Site Public Contact
240-964-1400
Boston, Massachusetts 02215
Site Public Contact
877-442-3324
Burlington, Massachusetts 01805
Foxborough, Massachusetts 02035
Site Public Contact
877-338-7425
Methuen, Massachusetts 01844
Site Public Contact
877-338-7425
Milford, Massachusetts 01757
Site Public Contact
877-332-4294
Peabody, Massachusetts 01960
South Weymouth, Massachusetts 02190
Site Public Contact
781-624-5000
Battle Creek, Michigan 49017
Brighton, Michigan 48114
Canton, Michigan 48188
Chelsea, Michigan 48118
Escanaba, Michigan 49829
Flint, Michigan 48503
Flint, Michigan 48503
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
Lansing, Michigan 48912
Livonia, Michigan 48154
Muskegon, Michigan 49444
Niles, Michigan 49120
Site Public Contact
616-391-1230
Norton Shores, Michigan 49444
Pontiac, Michigan 48341
Reed City, Michigan 49677
Saint Joseph, Michigan 49085
Saint Joseph, Michigan 49085
Traverse City, Michigan 49684
Wyoming, Michigan 49519
Ypsilanti, Michigan 48197
Bemidji, Minnesota 56601
Brainerd, Minnesota 56401
Burnsville, Minnesota 55337
Coon Rapids, Minnesota 55433
Deer River, Minnesota 56636
Duluth, Minnesota 55805
Edina, Minnesota 55435
Hibbing, Minnesota 55746
Site Public Contact
218-786-3308
Maplewood, Minnesota 55109
Minneapolis, Minnesota 55407
Minneapolis, Minnesota 55415
Minneapolis, Minnesota 55417
Site Public Contact
612-467-2800
Robbinsdale, Minnesota 55422
Saint Cloud, Minnesota 56303
Saint Louis Park, Minnesota 55416
Saint Paul, Minnesota 55101
Saint Paul, Minnesota 55102
Sandstone, Minnesota 55072
Shakopee, Minnesota 55379
Virginia, Minnesota 55792
Woodbury, Minnesota 55125
Columbus, Mississippi 39705
Grenada, Mississippi 38901
Jackson, Mississippi 39216
Site Public Contact
601-815-6700
New Albany, Mississippi 38652
Oxford, Mississippi 38655
Southhaven, Mississippi 38671
Cape Girardeau, Missouri 63703
City of Saint Peters, Missouri 63376
Creve Coeur, Missouri 63141
Farmington, Missouri 63640
Site Public Contact
314-996-5569
Sainte Genevieve, Missouri 63670
Site Public Contact
314-996-5569
St Louis, Missouri 63110
St Louis, Missouri 63128
St Louis, Missouri 63129
St Louis, Missouri 63131
Site Public Contact
314-996-5569
St Louis, Missouri 63136
St Louis, Missouri 63141
Site Public Contact
314-251-7066
Sullivan, Missouri 63080
Site Public Contact
314-996-5569
Sunset Hills, Missouri 63127
Site Public Contact
314-996-5569
Anaconda, Montana 59711
Billings, Montana 59101
Bozeman, Montana 59715
Great Falls, Montana 59405
Kalispell, Montana 59901
Missoula, Montana 59804
Lebanon, New Hampshire 03756
Basking Ridge, New Jersey 07920
Site Public Contact
212-639-7592
Cherry Hill, New Jersey 08002
Hackensack, New Jersey 07601
Site Public Contact
551-996-2897
Hamilton, New Jersey 08690
Site Public Contact
609-631-6946
Long Branch, New Jersey 07740
Middletown, New Jersey 07748
Site Public Contact
212-639-7592
Montvale, New Jersey 07645
Site Public Contact
212-639-7592
Morristown, New Jersey 07960
Site Public Contact
973-971-5900
New Brunswick, New Jersey 08903
Site Public Contact
732-235-7356
Newark, New Jersey 07101
Site Public Contact
732-235-7356
Sewell, New Jersey 08080
Somerville, New Jersey 08876
Summit, New Jersey 07902
Site Public Contact
908-522-2043
Albuquerque, New Mexico 87106
Buffalo, New York 14263
Camillus, New York 13031
Site Public Contact
315-472-7504
Commack, New York 11725
Site Public Contact
212-639-7592
East Syracuse, New York 13057
Site Public Contact
315-472-7504
Glens Falls, New York 12801
Site Public Contact
518-926-6700
Harrison, New York 10604
Site Public Contact
212-639-7592
New York, New York 10065
Site Public Contact
212-639-7592
The Bronx, New York 10461
Uniondale, New York 11553
Site Public Contact
212-639-7592
Cary, North Carolina 27518
Chapel Hill, North Carolina 27599
Durham, North Carolina 27710
Site Public Contact
888-275-3853
Durham, North Carolina 27713
Pinehurst, North Carolina 28374
Raleigh, North Carolina 27609
Bismarck, North Dakota 58501
Fargo, North Dakota 58103
Fargo, North Dakota 58122
Fargo, North Dakota 58122
Avon, Ohio 44011
Site Public Contact
800-641-2422
Beachwood, Ohio 44122
Canton, Ohio 44710
Centerville, Ohio 45459
Cleveland, Ohio 44106
Columbus, Ohio 43210
Dayton, Ohio 45409
Dayton, Ohio 45415
Franklin, Ohio 45005-1066
Greenville, Ohio 45331
Site Public Contact
937-569-7515
Kettering, Ohio 45429
Mentor, Ohio 44060
Troy, Ohio 45373
Lawton, Oklahoma 73505
Site Public Contact
877-231-4440
Oklahoma City, Oklahoma 73104
Newberg, Oregon 97132
Oregon City, Oregon 97045
Portland, Oregon 97213
Portland, Oregon 97225
Portland, Oregon 97239
Allentown, Pennsylvania 18103
Beaver, Pennsylvania 15009
Bethlehem, Pennsylvania 18017
Butler, Pennsylvania 16001
Danville, Pennsylvania 17822
Dickson City, Pennsylvania 18519
East Stroudsburg, Pennsylvania 18301
Erie, Pennsylvania 16505
Greensburg, Pennsylvania 15601
Site Public Contact
724-838-1900
Harrisburg, Pennsylvania 17109
Hazleton, Pennsylvania 18201
Hazleton, Pennsylvania 18201
Johnstown, Pennsylvania 15901
Site Public Contact
814-534-4724
Lewisburg, Pennsylvania 17837
Mechanicsburg, Pennsylvania 17050
Monroeville, Pennsylvania 15146
Philadelphia, Pennsylvania 19107
Philadelphia, Pennsylvania 19114
Pittsburgh, Pennsylvania 15232
Site Public Contact
412-647-8073
Pittsburgh, Pennsylvania 15237
Site Public Contact
412-367-6454
Pittsburgh, Pennsylvania 15243
Site Public Contact
412-502-3920
Scranton, Pennsylvania 18510
Wilkes-Barre, Pennsylvania 18711
Williamsport, Pennsylvania 17754
Westerly, Rhode Island 02891
Boiling Springs, South Carolina 29316
Charleston, South Carolina 29425
Easley, South Carolina 29640
Gaffney, South Carolina 29341
Georgetown, South Carolina 29440
Greenville, South Carolina 29605
Greenville, South Carolina 29605
Greenville, South Carolina 29615
Greer, South Carolina 29650
Greer, South Carolina 29651
Seneca, South Carolina 29672
Spartanburg, South Carolina 29303
Union, South Carolina 29379
Sioux Falls, South Dakota 57104
Sioux Falls, South Dakota 57117-5134
Collierville, Tennessee 38017
Memphis, Tennessee 38120
Nashville, Tennessee 37232
Site Public Contact
800-811-8480
Amarillo, Texas 79106
Baytown, Texas 77521
Cypress, Texas 77429
Dallas, Texas 75235
Dallas, Texas 75237
Dallas, Texas 75390
Fort Worth, Texas 76104
Houston, Texas 77030
Site Public Contact
713-790-2700
Houston, Texas 77070
Houston, Texas 77094
Site Public Contact
832-522-2873
Nassau Bay, Texas 77058
Richardson, Texas 75080
Sugar Land, Texas 77479
Site Public Contact
281-242-2873
The Woodlands, Texas 77385
Burlington, Vermont 05401
Burlington, Vermont 05405
Mechanicsville, Virginia 23116
Midlothian, Virginia 23114
Richmond, Virginia 23223
Richmond, Virginia 23226
Richmond, Virginia 23229
Richmond, Virginia 23235
Richmond, Virginia 23298
South Hill, Virginia 23970
Bridgeport, West Virginia 26330
Charleston, West Virginia 25304
Site Public Contact
304-388-9944
Martinsburg, West Virginia 25401
Morgantown, West Virginia 26506
Parkersburg, West Virginia 26101
Appleton, Wisconsin 54911
Ashland, Wisconsin 54806
Burlington, Wisconsin 53105
Cudahy, Wisconsin 53110
Germantown, Wisconsin 53022
Grafton, Wisconsin 53024
Green Bay, Wisconsin 54301
Green Bay, Wisconsin 54303
Green Bay, Wisconsin 54311
Kenosha, Wisconsin 53142
La Crosse, Wisconsin 54601
Madison, Wisconsin 53718
Madison, Wisconsin 53792
Marinette, Wisconsin 54143
Menomonee Falls, Wisconsin 53051
Site Public Contact
262-257-5100
Milwaukee, Wisconsin 53209
Milwaukee, Wisconsin 53215
Milwaukee, Wisconsin 53226
Site Public Contact
414-805-3666
Milwaukee, Wisconsin 53233
Mukwonago, Wisconsin 53149
New Richmond, Wisconsin 54017
Oak Creek, Wisconsin 53154
Site Public Contact
414-805-0505
Oconomowoc, Wisconsin 53066
Site Public Contact
262-928-7878
Oconto Falls, Wisconsin 54154
Oshkosh, Wisconsin 54904
Racine, Wisconsin 53406
Sheboygan, Wisconsin 53081
Sheboygan, Wisconsin 53081
Sheboygan, Wisconsin 53081
Sturgeon Bay, Wisconsin 54235-1495
Summit, Wisconsin 53066
Two Rivers, Wisconsin 54241
Waukesha, Wisconsin 53188
Site Public Contact
262-928-7632
Waukesha, Wisconsin 53188
Wauwatosa, Wisconsin 53226
West Allis, Wisconsin 53227
West Bend, Wisconsin 53095
Site Public Contact
414-805-0505
More Details
- NCT ID
- NCT06661720
- Status
- Recruiting
- Sponsor
- Alliance for Clinical Trials in Oncology
Detailed Description
PRIMARY OBJECTIVE: I. To compare disease free survival (DFS) as assessed by the investigator for high-risk renal cell carcinoma patients treated with adjuvant pembrolizumab and tivozanib versus those receiving pembrolizumab alone. SECONDARY OBJECTIVES: I. To compare overall survival (OS) for patients treated with adjuvant pembrolizumab and tivozanib versus those receiving pembrolizumab alone. II. To assess adverse events in each study arm by Common Terminology Criteria for Adverse Events (CTCAE) 5.0. BIOBANKING OBJECTIVE: I. To bank specimens for future unspecified research. QUALITY OF LIFE (QOL) OBJECTIVES: I. To compare global quality of life (QOL) for patients treated with pembrolizumab and tivozanib versus those receiving pembrolizumab alone. II. To compare patient-reported fatigue for patients treated with pembrolizumab and tivozanib versus those receiving pembrolizumab alone. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive pembrolizumab intravenously (IV) on days 1 and 43 of each cycle, or on days 1, 22, 43 and 64 of each cycle. Cycles repeat every 12 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and magnetic resonance imaging (MRI) or computed tomography (CT) throughout the trial and may undergo tissue biopsy on study. ARM II: Patients receive pembrolizumab IV on days 1 and 43 of each cycle and tivozanib orally (PO) once daily (QD) on days 1-21, days 29-49, and days 57-77 of each cycle for up to 6 months. Cycles repeat every 12 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and MRI or CT throughout the trial and may undergo tissue biopsy on study. After completion of study treatment, patients are followed up every 4 months for 2 years, then every 6 months for 3 years, then every subsequent year for 5 years.